LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 106

Search options

  1. Book: Allergic skin diseases

    Ong, Peck Y.

    (Immunology and allergy clinics of North America ; volume 37, number 1 (February 2017))

    2017  

    Author's details editors Peck Y. Ong, Peter Schmid-Grendelmeier
    Series title Immunology and allergy clinics of North America ; volume 37, number 1 (February 2017)
    Collection
    Language English
    Size xvi, 231 Seiten, Illustrationen
    Publisher Elsevier
    Publishing place Philadelphia, Pennsylvania
    Publishing country United States
    Document type Book
    HBZ-ID HT019246655
    ISBN 978-0-323-49651-3 ; 0-323-49651-2
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  2. Article ; Online: The chicken or the egg of lymphopenia in atopic eczema.

    Ong, Peck Y

    Journal of the European Academy of Dermatology and Venereology : JEADV

    2023  Volume 37, Issue 6, Page(s) 1097–1098

    MeSH term(s) Humans ; Allergens ; Dermatitis, Atopic/complications ; Eczema/complications ; Lymphopenia/complications
    Chemical Substances Allergens
    Language English
    Publishing date 2023-05-12
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 1128828-0
    ISSN 1468-3083 ; 0926-9959
    ISSN (online) 1468-3083
    ISSN 0926-9959
    DOI 10.1111/jdv.19086
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Constant vigilance! Managing threats to the skin barrier.

    Chu, Vanessa / Ong, Peck Y

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology

    2024  

    Abstract: Objective: Skin barrier defects are one of the primary causes of atopic dermatitis (AD). The basis of skin barrier defects in AD is due to a deficiency in various barrier proteins including filaggrin, involucrin, claudins, and lipids such as ceramide, ... ...

    Abstract Objective: Skin barrier defects are one of the primary causes of atopic dermatitis (AD). The basis of skin barrier defects in AD is due to a deficiency in various barrier proteins including filaggrin, involucrin, claudins, and lipids such as ceramide, fatty acids, and cholesterol. This review updates a more detailed lipid dysregulation in the skin barrier of AD based on recent lipidomic analysis. The clinical implications, treatments, prevention, and predictive capability of skin barrier defects are also reviewed.
    Data sources: Published literature obtained through PubMed searches.
    Study selections: Studies relevant to the mechanisms, clinical implications, treatments, prevention, and predictors of AD development.
    Results: Skin barrier defects contribute to transepidermal water loss, infections, IgE sensitizations, and cutaneous inflammation in AD. Preventive treatments include daily hydration and application of moisturizers. Because skin barrier defects precede the development of AD, they provide an opportunity for prediction and intervention.
    Conclusion: Skin barrier defects play an important role in the comorbidities of AD including infectious complications, disease flare, and allergic diathesis. Current research focuses on prevention and prediction of AD development.
    Language English
    Publishing date 2024-02-13
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1228189-x
    ISSN 1534-4436 ; 0003-4738 ; 1081-1206
    ISSN (online) 1534-4436
    ISSN 0003-4738 ; 1081-1206
    DOI 10.1016/j.anai.2024.02.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Atopic dermatitis: Is innate or adaptive immunity in control? A clinical perspective.

    Ong, Peck Y

    Frontiers in immunology

    2022  Volume 13, Page(s) 943640

    Abstract: Atopic dermatitis (AD) is a chronic inflammatory skin disease with barrier defects and immune dysregulations. The pathogenesis of AD involves the physical barrier as well as epithelial cells, which are considered a vital part of the innate immunity of ... ...

    Abstract Atopic dermatitis (AD) is a chronic inflammatory skin disease with barrier defects and immune dysregulations. The pathogenesis of AD involves the physical barrier as well as epithelial cells, which are considered a vital part of the innate immunity of the skin. The importance of filaggrin mutations in the pathogenesis of AD has also been well-established with reproducible results around the world in multiple studies and ethnic groups. This protein plays an important role in skin barrier functions and further reaffirms barrier defects as one of the primary causes of AD. The main epithelial cells, keratinocytes, function as a major sentinel for the skin in detecting danger signals or microbial pathogens, and trigger downstream immune responses. In AD, these cells express TSLP, IL-33 and IL-25, which lead to downstream systemic production of type 2 cytokines. In spite of major advances in our understanding of the innate immunity of AD, recent success in the systemic therapeutics of AD have focused on targeting the products of the adaptive immunity, particularly cytokines produced by T cells. In addition to type 2 cytokines, type 17 cytokines have also been implicated in the pathogenesis of AD. The current review examines the implications of these cytokines in AD from clinical perspectives.
    MeSH term(s) Adaptive Immunity ; Cytokines/metabolism ; Dermatitis, Atopic ; Humans ; Immunity, Innate ; Skin
    Chemical Substances Cytokines
    Language English
    Publishing date 2022-07-27
    Publishing country Switzerland
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2022.943640
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Academic interest of allergists in atopic dermatitis before and after approval of systemic immunomodulators.

    Zhang, Sarah / Ong, Peck Y

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology

    2023  Volume 131, Issue 6, Page(s) 779–781

    MeSH term(s) Humans ; Dermatitis, Atopic/drug therapy ; Allergists ; Immunologic Factors
    Chemical Substances Immunologic Factors
    Language English
    Publishing date 2023-08-28
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1228189-x
    ISSN 1534-4436 ; 0003-4738 ; 1081-1206
    ISSN (online) 1534-4436
    ISSN 0003-4738 ; 1081-1206
    DOI 10.1016/j.anai.2023.08.593
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: The PATHOGENesis of Food Allergy.

    Ong, Peck Y

    Frontiers in pediatrics

    2019  Volume 7, Page(s) 484

    Language English
    Publishing date 2019-11-21
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2711999-3
    ISSN 2296-2360
    ISSN 2296-2360
    DOI 10.3389/fped.2019.00484
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Comparison of Old and New Systemic Treatments for Moderate to Severe Atopic Dermatitis.

    Yim, Hyun J / Jean, Tiffany / Ong, Peck Y

    Current allergy and asthma reports

    2024  

    Abstract: Purpose of review: Historically, systemic treatments for atopic dermatitis (AD) primarily consisted of immunosuppressive agents such as corticosteroids and Disease Modifying Antirheumatic Drugs (DMARDS), which provided symptomatic relief but often had ... ...

    Abstract Purpose of review: Historically, systemic treatments for atopic dermatitis (AD) primarily consisted of immunosuppressive agents such as corticosteroids and Disease Modifying Antirheumatic Drugs (DMARDS), which provided symptomatic relief but often had long-term adverse effects. Newer treatments have shown significant efficacy with less side effects in clinical trials. This review discusses and compares conventional and newer systemic treatments for AD.
    Recent findings: Newer medications for AD including dupilumab, tralokinumab, lebrikizumab, and oral JAK inhibitors have been shown to be safe and efficacious. High dose cyclosporine and dupilumab were more effective than methotrexate and azathioprine in improving clinical signs of AD. High-dose upadacitinib was shown in another meta-analysis to be most effective in the measured outcomes but had the highest frequency of adverse events. Targeted biologic treatments are increasingly favored over traditional immunosuppressive treatments of AD. Treatment can be individualized based on potency, adverse side effects, mechanism of action, and administration preference. Ongoing research continues to expand treatment options for AD.
    Language English
    Publishing date 2024-04-18
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2057370-4
    ISSN 1534-6315 ; 1529-7322
    ISSN (online) 1534-6315
    ISSN 1529-7322
    DOI 10.1007/s11882-024-01145-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Elevated serum total IgE is associated with eczema exacerbation in children hospitalized for atopic dermatitis.

    Atwal, Sanmeet / Ong, Peck Y

    Pediatric dermatology

    2023  Volume 40, Issue 2, Page(s) 301–304

    Abstract: Background/objectives: Atopic dermatitis (AD) can be a debilitating skin condition, often leading to hospitalization due to severe AD exacerbations or infectious complications. As both AD exacerbations and infectious complications can present similarly, ...

    Abstract Background/objectives: Atopic dermatitis (AD) can be a debilitating skin condition, often leading to hospitalization due to severe AD exacerbations or infectious complications. As both AD exacerbations and infectious complications can present similarly, it can be difficult to distinguish the two conditions. Thus, we aimed to evaluate if there is any difference in serum IgE levels in children with AD who were hospitalized for AD exacerbation and for AD-associated infectious complications.
    Methods: A retrospective chart review was performed on hospitalized children with AD exacerbations and AD-associated infectious complications over a 17-year span. Data including length of stay, primary diagnosis, systemic antibiotics, laboratory, and bacterial culture results were collected. Serum total immunoglobulin E (IgE) levels were adjusted by age. Age, length of stay, total IgE levels, and age-adjusted IgE levels were compared using t-test. Logistic regression was used for age-adjusted IgE levels.
    Results: The mean serum total IgE level in subjects with AD exacerbation was 9603 ± 15,873 kU/L, which was significantly higher than that of subjects with infectious complications at 3167 ± 5486 kU/L (p = .029). Logistic regression revealed that subjects with an age-adjusted IgE of >4 had more than 3-fold odds of having AD exacerbation than infectious complications.
    Conclusions: Our results suggest that total IgE levels are higher in children who were hospitalized for AD exacerbation than those with AD-associated infectious complications.
    MeSH term(s) Humans ; Child ; Dermatitis, Atopic/diagnosis ; Retrospective Studies ; Immunoglobulin E ; Hospitalization ; Eczema
    Chemical Substances Immunoglobulin E (37341-29-0)
    Language English
    Publishing date 2023-01-19
    Publishing country United States
    Document type Journal Article
    ZDB-ID 605539-4
    ISSN 1525-1470 ; 0736-8046
    ISSN (online) 1525-1470
    ISSN 0736-8046
    DOI 10.1111/pde.15245
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Successful use of dupilumab to treat eczema in a child with X-linked agammaglobulinemia.

    Atwal, Sanmeet / Ong, Peck Y

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology

    2022  Volume 129, Issue 3, Page(s) 384–386

    MeSH term(s) Agammaglobulinemia/complications ; Agammaglobulinemia/drug therapy ; Antibodies, Monoclonal, Humanized/therapeutic use ; Child ; Eczema/drug therapy ; Genetic Diseases, X-Linked ; Humans ; Treatment Outcome
    Chemical Substances Antibodies, Monoclonal, Humanized ; dupilumab (420K487FSG)
    Language English
    Publishing date 2022-06-28
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1228189-x
    ISSN 1534-4436 ; 0003-4738 ; 1081-1206
    ISSN (online) 1534-4436
    ISSN 0003-4738 ; 1081-1206
    DOI 10.1016/j.anai.2022.06.020
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: The Genetics of Eczema Herpeticum.

    Hodara, Elisabeth / Ong, Peck Y

    Clinical reviews in allergy & immunology

    2022  Volume 63, Issue 3, Page(s) 390–397

    Abstract: Eczema herpeticum (EH) is a viral skin infection caused by herpes simplex virus (HSV) superimposed on eczematous skin lesions in atopic dermatitis (AD). Though the pathogenesis of EH has yet to be fully elucidated, the fact that EH is relatively rare ... ...

    Abstract Eczema herpeticum (EH) is a viral skin infection caused by herpes simplex virus (HSV) superimposed on eczematous skin lesions in atopic dermatitis (AD). Though the pathogenesis of EH has yet to be fully elucidated, the fact that EH is relatively rare despite a majority of adults showing serologic evidence of HSV exposure points to a genetic component predisposing to the disease. A number of genetic variants have been isolated in EH which may help distinguish a subgroup of patients susceptible to developing the condition. These unique genetic characteristics include deficiencies in skin barrier function and hydration, as well as at the level of the immune system. In this review, we summarize the genetic findings associated with EH identified to date. Isolating genetic markers in EH will be instrumental in stratifying patients at risk for EH and will have significant implications in the development and tailoring of targeted therapies.
    MeSH term(s) Adult ; Humans ; Kaposi Varicelliform Eruption/genetics ; Simplexvirus/genetics ; Herpes Simplex ; Dermatitis, Atopic ; Disease Susceptibility ; Eczema
    Language English
    Publishing date 2022-09-17
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1239045-8
    ISSN 1559-0267 ; 1080-0549
    ISSN (online) 1559-0267
    ISSN 1080-0549
    DOI 10.1007/s12016-022-08953-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top